AR063773A1 - Uso de composiciones nutricionales para prevenir trastornos - Google Patents

Uso de composiciones nutricionales para prevenir trastornos

Info

Publication number
AR063773A1
AR063773A1 ARP070104861A ARP070104861A AR063773A1 AR 063773 A1 AR063773 A1 AR 063773A1 AR P070104861 A ARP070104861 A AR P070104861A AR P070104861 A ARP070104861 A AR P070104861A AR 063773 A1 AR063773 A1 AR 063773A1
Authority
AR
Argentina
Prior art keywords
months
prevent
age
fatty acids
disorder
Prior art date
Application number
ARP070104861A
Other languages
English (en)
Inventor
Renate Maria Louise Zwijsen
Der Beek Eline Marleen Van
Gunther Boehm
De Heijning Hubertus Josep Van
Laere Katrien Maria Jozefa Van
Original Assignee
Nutricia Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38222322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR063773(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nutricia Nv filed Critical Nutricia Nv
Publication of AR063773A1 publication Critical patent/AR063773A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/156—Flavoured milk preparations ; Addition of fruits, vegetables, sugars, sugar alcohols or sweeteners
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1526—Amino acids; Peptides; Protein hydrolysates; Nucleic acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/152—Milk preparations; Milk powder or milk powder preparations containing additives
    • A23C9/1528—Fatty acids; Mono- or diglycerides; Petroleum jelly; Paraffine; Phospholipids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Pediatric Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

Un método para prevenir y/o tratar adiposidad viseral y/o alterar la distribución de la grasa corporal mediante la administración de cierta composición nutricional a un sujeto humano a la edad de entre 0 y 48 meses, y prevenir la aparición de enfermedades en etapas posteriores de la vida. Reivindicación 1: El uso de la composición que comprende un componente lipídico, proteico y de hidrato de carbono digestible en donde el componente de lípido provee el 35 al 55% del total de calorías, el componente de proteína provee 5 a 15% del total de calorías y el componente de hidrato de carbono digestible provee el 30 al 60% del total de calorías, donde el componente lipídico comprende (i) ácido linoleico (LA) y ácido alfa-linoléico (ALA) en una relación de peso de LA/ALA entre 2 y 6 (ii) menos de 14,5% en peso de LA sobre la base de ácidos grasos totales, (iii) ácidos grasos poliinsaturados de cadena larga (LC-PUFA); y opcionalmente (iv) 10-50% en peso de ácidos grasos de cadena larga (MCFA) para la fabricación de una composición que se administra a un humano no obeso de una edad inferior de 36 meses y para prevenir el desarrollo de un trastorno cuando dicho humano tiene una edad superior a 36 meses, en donde dicho trastorno se selecciona del grupo que consiste en diabetes de tipo 2, hipoglucemia en ayunas, resistencia a insulina, adiposidad visceral, hiperinsulinemia, hipertensión, enfermedad cardiovascular, enfermedad cerebrovascular, arterioesclerosis, dislipidemia, hiperuricemia, hídago graso, osteoartritis y apnea de sueno. Reivindicación 7: El uso de acuerdo con una de las reivindicaciónes precedentes para evitar el desarrollo de un trastorno seleccionado del grupo que consiste en diabetes, adiposidad visceral y/o enfermedades cardiovasculares. Reivindicación 8: El uso de acuerdo con una de las reivindicaciones precedentes, donde la composición nutricional se administra a un sujeto humano con una edad inferior de 18 meses.
ARP070104861A 2006-11-02 2007-10-31 Uso de composiciones nutricionales para prevenir trastornos AR063773A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/NL2006/050274 WO2008054192A1 (en) 2006-11-02 2006-11-02 Use of nutritional compositions for preventing disorders

Publications (1)

Publication Number Publication Date
AR063773A1 true AR063773A1 (es) 2009-02-18

Family

ID=38222322

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP070104862A AR063774A1 (es) 2006-11-02 2007-10-31 Uso de composiciones nutricionales para prevenir trastornos
ARP070104861A AR063773A1 (es) 2006-11-02 2007-10-31 Uso de composiciones nutricionales para prevenir trastornos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP070104862A AR063774A1 (es) 2006-11-02 2007-10-31 Uso de composiciones nutricionales para prevenir trastornos

Country Status (14)

Country Link
US (3) US20100068149A1 (es)
EP (6) EP3025643B1 (es)
JP (1) JP2010509210A (es)
CN (3) CN101568361B (es)
AR (2) AR063774A1 (es)
AU (2) AU2007314721B2 (es)
BR (1) BRPI0717969A2 (es)
CA (2) CA2667856C (es)
ES (1) ES2571856T3 (es)
MY (1) MY151018A (es)
NZ (2) NZ569264A (es)
PL (1) PL2077902T3 (es)
RU (2) RU2446827C2 (es)
WO (3) WO2008054192A1 (es)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8541472B2 (en) * 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
JP5238373B2 (ja) * 2008-06-25 2013-07-17 株式会社ヤクルト本社 腸間膜脂肪低減剤
EP2554056B1 (en) 2008-09-02 2019-12-04 N.V. Nutricia Nutritional compositions with large diameter lipid globules with a coating comprising phospholipids
EP2452574A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for young infants
SG172774A1 (en) 2009-01-19 2011-08-29 Nestec Sa Nutritional composition for infants
WO2010106384A1 (fr) * 2009-03-16 2010-09-23 Societe La Biochimie Appliquee (Solabia) Compositions nutraceutiques, pharmaceutiques ou alimentaires a base de gluco-oligosaccharides
AU2010230362B2 (en) 2009-04-01 2015-01-15 Société des Produits Nestlé S.A. Reduction of risk of obesity
PL2413952T3 (pl) 2009-04-03 2017-08-31 Nestec S.A. Polepszenie promowania zdrowego doganiania wzrostu
WO2010119088A2 (en) * 2009-04-15 2010-10-21 Bodo Melnik Milk and milk-based products modified to exhibit a reduced insulinemic index and/or reduced mitogenic activity
WO2010134800A1 (en) 2009-05-19 2010-11-25 N.V. Nutricia Human milk fortifier with high protein and long chain poly unsaturated fatty acids for improving body adipose tissue distribution
WO2011071365A1 (en) 2009-12-07 2011-06-16 N.V. Nutricia Balanced fat composition and use thereof in a liquid nutritional composition suitable for enteral feeding
EP2353595B1 (en) 2010-01-19 2015-10-28 MJN U.S. Holdings LLC Nutritional compensation for western-type diet
US20110208153A1 (en) * 2010-02-24 2011-08-25 John Alvey Formulations and methods for nutrient delivery
WO2011115476A1 (en) * 2010-03-17 2011-09-22 N.V. Nutricia Infant nutrition for improving fatty acid composition of brain membranes later in life
WO2011119023A1 (en) * 2010-03-26 2011-09-29 N.V. Nutricia Low protein infant formula with increased essential amino acids
WO2012009426A1 (en) * 2010-07-13 2012-01-19 Abbott Laboratories High tolerance infant formula including hydrolyzed protein
EP2452571A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Array of complementary infant/young child nutritional compositions
EP2452572A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional formula with particularly adapted caloric density for infants and children
EP2452573A1 (en) * 2010-11-15 2012-05-16 Nestec S.A. Age-tailored nutritional composition with animal fats and vegetable fats
EP2502507A1 (en) * 2011-03-21 2012-09-26 Abbott Laboratories Methods for improving bone health in infants using prebiotics
WO2012173467A1 (en) 2011-06-16 2012-12-20 N.V. Nutricia Metabolic imprinting effects of specifically designed lipid component
WO2012177118A1 (en) * 2011-06-22 2012-12-27 N.V. Nutricia Method for reducing the occurrence of infection in young children
WO2013036103A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with large lipid globules
WO2013036102A1 (en) 2011-09-08 2013-03-14 N.V. Nutricia Use of infant formula with cholesterol
JP5718293B2 (ja) 2011-09-15 2015-05-13 花王株式会社 Ｇｉｐ上昇抑制剤
EP2774615A4 (en) * 2011-10-17 2016-02-17 Kao Corp AGENT FOR INCREASING THE QUANTITY OF MUSCLES
CA2863739C (en) * 2012-02-17 2020-07-14 Alcresta, Inc. Methods, compositions, and devices for supplying dietary fatty acid needs
SE536599C3 (sv) * 2012-04-10 2017-01-10 Hero Ag Näringssammansättning med lågt kalori- och lågt proteininnehåll
US9289461B2 (en) 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
US10251928B2 (en) 2014-11-06 2019-04-09 Mead Johnson Nutrition Company Nutritional supplements containing a peptide component and uses thereof
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US20140328970A1 (en) * 2013-05-03 2014-11-06 Mead Johnson Nutrition Company Nutritional Composition Comprising Whey and Hydrolyzed Casein and Uses Thereof
US20160124002A1 (en) * 2013-06-14 2016-05-05 Seoul National University R&Db Foundation Method for detecting hypoxia or diagnosing hypoxia-related diseases
KR101446873B1 (ko) 2013-06-14 2014-10-06 서울대학교산학협력단 수면 무호흡증 진단용 생체 표지자 및 그 용도
WO2015013678A2 (en) * 2013-07-25 2015-01-29 Iycus, Llc Stable fatty acid compositions
CN104413147A (zh) * 2013-09-11 2015-03-18 中粮营养健康研究院有限公司 一种用于配方奶粉的油脂组合物、其制备方法及其用途
WO2015065193A1 (en) 2013-11-01 2015-05-07 N.V. Nutricia Lipid composition for improving body composition during catch-up growth
MX2016006577A (es) * 2013-11-29 2016-08-03 Nestec Sa Uso de composiciones nutritivas que tienen una cantidad baja de proteina.
US10821150B2 (en) 2013-11-29 2020-11-03 Societe Des Produits Nestle S.A. Infant nutrition for improvement in insulin sensitivity later in life
WO2016050754A1 (en) * 2014-09-30 2016-04-07 Nestec S.A. Nutritional composition with low content of medium-chain fatty acids in specific proportions, and its uses.
US10881674B2 (en) 2014-12-08 2021-01-05 Glycom A/S Synthetic composition for treating metabolic disorders
US10987368B2 (en) * 2014-12-08 2021-04-27 Glycom A/S Synthetic composition for preventing or treating CVD
US20180067129A1 (en) * 2015-03-17 2018-03-08 Duke University Compositions and Methods for Identifying and Modulating Metabolic Health
JP6613661B2 (ja) * 2015-07-08 2019-12-04 花王株式会社 食品に対する内臓脂肪のつきにくさの評価方法
US10258590B2 (en) 2015-10-14 2019-04-16 Alcresta Therapeutics, Inc. Enteral feeding device and related methods of use
ES2742522T3 (es) 2015-10-15 2020-02-14 Nutricia Nv Fórmulas para lactantes con arquitectura lipídica especial para promover el crecimiento saludable
PL3362061T3 (pl) * 2015-10-15 2024-03-04 N.V. Nutricia Mieszanka dla niemowląt z tłuszczem mlecznym wspomagająca zdrowy wzrost
CN108697142A (zh) 2016-01-26 2018-10-23 雀巢产品技术援助有限公司 用于控制婴儿或幼儿的食物摄入量和生长的包含2FL和LNnT的组合物
US11388922B2 (en) 2016-04-11 2022-07-19 Societe Des Produits Nestle S.A. Infant nutrition delivering metabolic benefits
EP3841892A1 (en) * 2016-05-10 2021-06-30 N.V. Nutricia Fermented infant formula
RU2748025C2 (ru) 2016-12-09 2021-05-19 Н.В. Нютрисиа Питательный состав для улучшения клеточных мембран
AU2018222626A1 (en) * 2017-02-20 2019-07-18 Societe Des Produits Nestle S.A. Nutritional compositions with partially hydrolysed proteins for use in inducing glucose and/or insulin response(s) close to the ones observed with human milk
US11045396B2 (en) 2017-08-17 2021-06-29 Alcresta Therapeutics, Inc. Devices and methods for the supplementation of a nutritional formula
US20210177031A1 (en) * 2017-11-09 2021-06-17 Societe Des Produits Nestle S.A. An array of age-tailored nutritional formula for infants and young children for use in the prevention of sub-optimal body composition
WO2019168149A1 (ja) 2018-03-02 2019-09-06 一般財団法人糧食研究会 認知機能を改善するペプチド
JP7032533B2 (ja) * 2018-07-13 2022-03-08 古野電気株式会社 超音波撮像装置、超音波撮像システム、超音波撮像方法および超音波撮像プログラム
EP3920723A1 (en) * 2019-02-04 2021-12-15 N.V. Nutricia Fermented formula with non digestible oligosaccharides for sleep improvement
KR20230011679A (ko) * 2021-07-14 2023-01-25 최명석 비만의 예방을 위한 식이조성물
RU2761163C1 (ru) * 2021-07-16 2021-12-06 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр питания, биотехнологии и безопасности пищи Специализированный пищевой продукт, предназначенный для питания больных в период лечения неалкогольной жировой болезни печени
RU2761164C1 (ru) * 2021-07-16 2021-12-06 Федеральное государственное бюджетное учреждение науки Федеральный исследовательский центр питания, биотехнологии и безопасности пищи Способ лечения больных неалкогольной жировой болезнью печени с использованием специализированного пищевого продукта
CN115736261A (zh) * 2022-12-07 2023-03-07 中国科学院深圳先进技术研究院 一种生酮饮食组合物及其制备方法和应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1062873A1 (en) * 1999-12-13 2000-12-27 N.V. Nutricia Improved infant formula, protein hydrolysate for use in such an infant formula, and method for producing such a hydrolysate
US6495599B2 (en) * 2000-04-13 2002-12-17 Abbott Laboratories Infant formulas containing long-chain polyunsaturated fatty acids and uses therof
US20050019372A1 (en) * 2001-07-10 2005-01-27 Barbara E Corkey Modified-fat nutritional products useful preventing or treating obesity
IL158554A0 (en) * 2003-10-22 2004-05-12 Enzymotec Ltd Mimetic lipids as dietary supplements
PT1721612E (pt) 2003-10-24 2009-09-02 Nutricia Nv Oligossacarídeos imunomoduladores
WO2005063050A1 (en) 2003-12-19 2005-07-14 Abbott Laboratories Method of increasing lean body mass and reducing body fat mass in infants
US7413295B2 (en) * 2004-03-19 2008-08-19 Brother Kogyo Kabushiki Kaisha Inkjet printer with delivery chamber
CN101022821B (zh) * 2004-07-19 2014-01-29 纽崔西亚公司 天冬氨酸用于调节血中葡萄糖水平的用途
EP1634599A1 (en) * 2004-08-20 2006-03-15 N.V. Nutricia Iimmune stimulatory infant nutrition
EP1656839A1 (en) * 2004-11-11 2006-05-17 N.V. Nutricia Nutrition containing lipid blend
DE602004015169D1 (de) * 2004-11-26 2008-08-28 Nutricia Nv Kleinkindernahrung mit proteasehemmer
WO2006069918A1 (en) 2004-12-27 2006-07-06 Nestec S.A. Use of infant formula with reduced protein content
FI20055090A (fi) * 2005-02-24 2006-08-25 Elcoteq Se Lukitusväline
EP2805625B2 (en) * 2005-02-28 2022-11-23 N.V. Nutricia Nutritional composition with prebiotics and probiotics
ES2350907T3 (es) 2005-07-01 2011-01-28 N.V. Nutricia Nutrición para bebés con proteínas hidrolizadas.
WO2008054192A1 (en) * 2006-11-02 2008-05-08 N.V. Nutricia Use of nutritional compositions for preventing disorders
AU2006327996B2 (en) * 2005-12-23 2012-03-29 N.V. Nutricia Infant nutritional compositions for preventing obesity
US20090220973A1 (en) * 2006-04-03 2009-09-03 Joslin Diabetes Center, Inc. Obesity and body fat distribution

Also Published As

Publication number Publication date
CA2667856A1 (en) 2008-05-08
AU2007314721B2 (en) 2013-09-05
AU2007314721A1 (en) 2008-05-08
WO2008054208A3 (en) 2008-10-16
EP3335710A2 (en) 2018-06-20
AU2007314729B2 (en) 2013-04-18
RU2009120668A (ru) 2010-12-10
EP2077902A2 (en) 2009-07-15
AR063774A1 (es) 2009-02-18
CN101568361B (zh) 2016-08-17
EP3025643A1 (en) 2016-06-01
CN101568361A (zh) 2009-10-28
NZ569264A (en) 2011-09-30
RU2446827C2 (ru) 2012-04-10
WO2008054192A1 (en) 2008-05-08
RU2009120708A (ru) 2010-12-10
RU2444912C2 (ru) 2012-03-20
AU2007314729A1 (en) 2008-05-08
EP3025643B1 (en) 2017-11-29
EP2510811A3 (en) 2018-01-03
EP2077728B1 (en) 2016-12-21
CA2667759A1 (en) 2008-05-08
JP2010509210A (ja) 2010-03-25
CN106172792A (zh) 2016-12-07
US20150094257A1 (en) 2015-04-02
ES2571856T3 (es) 2016-05-27
NZ576665A (en) 2012-01-12
EP2508178A3 (en) 2018-01-03
WO2008054200A2 (en) 2008-05-08
CN101573048B (zh) 2013-12-25
WO2008054208A2 (en) 2008-05-08
EP2077902B1 (en) 2016-03-23
CA2667856C (en) 2015-11-24
CN101573048A (zh) 2009-11-04
EP3335710A3 (en) 2018-09-12
BRPI0717969A2 (pt) 2013-11-12
EP2510811A2 (en) 2012-10-17
PL2077902T3 (pl) 2016-09-30
US20100075900A1 (en) 2010-03-25
US20100068149A1 (en) 2010-03-18
EP2508178A2 (en) 2012-10-10
WO2008054200A3 (en) 2009-05-07
MY151018A (en) 2014-03-31
EP2077728A2 (en) 2009-07-15

Similar Documents

Publication Publication Date Title
AR063773A1 (es) Uso de composiciones nutricionales para prevenir trastornos
AR058752A1 (es) Composiciones para bebes para prevenir la obesidad
Mansour et al. Nutrients related to GLP1 secretory responses
Kim et al. Functional amino acids and fatty acids for enhancing production performance of sows and piglets
Uauy et al. Essential fat requirements of preterm infants
ES2531599T3 (es) Utilización de triglicéridos docosahexaenoicos para el tratamiento de enfermedades tumorales
US10451609B1 (en) Omega-3 fatty acid nutriceutical composition and optimization method
Gatrell et al. Creating ω-3 fatty-acid-enriched chicken using defatted green microalgal biomass
ES2570774T3 (es) Uso de ácido araquidónico para reducir el riesgo de resistencia a la insulina más adelante en la vida
ATE508642T1 (de) Hydroxytyrosol-verstärkte öle und deren verwendung
JP2011528555A5 (es)
Volatiana et al. Tributyrin‐supplemented high‐soya bean meal diets of juvenile black sea bream, Acanthopagrus schlegelii: Study on growth performance and intestinal morphology and structure
JP2011528556A5 (es)
Sansbury et al. Antiobesogenic role of endothelial nitric oxide synthase
Jayawardena et al. Sarcopenia; functional concerns, molecular mechanisms involved, and seafood as a nutritional intervention–review article
AR083460A1 (es) Hidrolizados de proteinas animales de origen marino con propiedades neuroprotectoras
Martin et al. Maternal Diet Supplementation with n‐6/n‐3 Essential Fatty Acids in a 1.2: 1.0 Ratio Attenuates Metabolic Dysfunction in MSG‐Induced Obese Mice
JP6180485B2 (ja) オイル組成物、オイル組成物を含む製剤、及び内蔵脂肪の蓄積を減らし、ブドウ糖耐性を向上させて肥満関連疾患及び障害を予防又は治療するためのその使用
WO2010133377A8 (en) Fat blends and uses thereof
KR20200061344A (ko) 비알코올성 지방성 간 질환의 비인간 모델 동물
JP2020092691A (ja) ケトン食用栄養組成物
US10925849B2 (en) Method of treatment of obesity
US12023313B2 (en) Method of treatment of obesity
US11266665B1 (en) Omega-3 fatty acid nutriceutical compositions and methods
DE602004014716D1 (de) Use of unsaturated fatty acids for the reduction of appetite or food intake

Legal Events

Date Code Title Description
FB Suspension of granting procedure